Evaluating the effect of teriflunomide on whole brain atrophy in the phase 3 TOPIC study

被引：0
|
作者：
Zivadinov, R. [1 ]
Dwyer, M. G. [1 ]
Carl, E. [1 ]
Thangavelu, K. [2 ]
Cavalier, S. [2 ]
Bergsland, N. [1 ]
机构：
[1] SUNY Buffalo, Buffalo, NY USA
[2] Sanofi, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P870
引用
收藏
页码：463 / 463
页数：1
相关论文
共 50 条
  • [1] Evaluating the Effect of Teriflunomide on Cortical Gray Matter Atrophy in the Phase 3 TOPIC Study
    Zivadinov, Robert
    Dwyer, Michael
    Carl, Ellen
    Thangavelu, Karthinathan
    Cavalier, Steven
    Bergsland, Niels
    NEUROLOGY, 2017, 88
  • [2] Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study
    Sprenger, Till
    Lebrun-Frenay, Christine
    Vermersch, Patrick
    Park, Min Su
    Chinchilla, Dennis
    McCombe, Pamela
    Lincoln, John
    Kappos, Ludwig
    Bergsland, Niels
    Dwyer, Michael
    Cavalier, Steven
    Roesch, Nora
    Somera-Molina, Kathleen
    Poole, Elizabeth
    Zivadinov, Robert
    NEUROLOGY, 2019, 92 (15)
  • [3] Evaluating effect of teriflunomide on cortical atrophy in a subgroup analysis of patients defined by baseline MRI activity in the Phase 3 TOPIC study
    Zivadinov, R.
    Dwyer, M. G.
    Carl, E.
    Thangavelu, K.
    Cavalier, S.
    Bergsland, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 580 - 580
  • [4] Effect of teriflunomide on MRI activity in patients with early MS: outcomes from the phase 3 TOPIC study
    Wolinsky, J. S.
    Comi, G.
    Kappos, L.
    Bauer, D.
    Truffinet, P.
    Miller, A. E.
    JOURNAL OF NEUROLOGY, 2014, 261 : S75 - S75
  • [5] Investigating the effect of teriflunomide on diffuse cortical grey matter volume loss in the phase 3 TOPIC study
    Sprenger, T.
    Lebrun-Frenay, C.
    Vermersch, P.
    Park, M. S.
    Chinchilla, D.
    McCombe, P.
    Lincoln, J.
    Bergsland, N.
    Dwyer, M.
    Kappos, L.
    Cavalier, S.
    Roesch, N.
    Guce, M.
    Poole, E.
    Zivadinov, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 864 - 864
  • [6] Effect of teriflunomide on MRI activity in patients with early MS: outcomes from the phase 3 TOPIC study
    Wolinsky, J. S.
    Comi, G.
    Kappos, L.
    Bauer, D.
    Truffinet, P.
    Miller, A. E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 103 - 103
  • [7] Investigating the effect of teriflunomide on diffuse brain tissue damage in the phase 3 TEMSO study
    Sprenger, T.
    Comi, G.
    Lebrun-Frenay, C.
    Park, M.
    Chinchillas, D.
    Lincoln, J. A.
    Kappos, L.
    Radue, E. -W.
    Lublin, A.
    Cavalier, S.
    Thangavelu, K.
    Wuerfel, J.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 485 - 486
  • [8] Evaluating the Effect of Intensity Standardisation on Longitudinal Whole Brain Atrophy Quantification in Brain Magnetic Resonance Imaging
    Carvajal-Camelo, Emily E.
    Bernal, Jose
    Oliver, Arnau
    Llado, Xavier
    Trujillo, Maria
    APPLIED SCIENCES-BASEL, 2021, 11 (04): : 1 - 19
  • [9] Efficacy of teriflunomide in MS patients with a primary presentation of optic neuritis: a subgroup analysis from the phase 3 TOPIC study
    Miller, A. E.
    Rog, D.
    Thangavelu, K.
    Truffinet, P.
    Cavalier, S.
    Wolinsky, J. S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 531 - 532
  • [10] MRI outcomes in patients with early multiple sclerosis treated with teriflunomide: subgroup analyses from the TOPIC phase 3 study
    Wolinsky, J. S.
    Truffinet, P.
    Bauer, D.
    Miller, A. E.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 84 - 84
12345